GT Biopharma (NASDAQ:GTBP) vs. Puma Biotechnology (NASDAQ:PBYI) Head-To-Head Comparison

GT Biopharma (NASDAQ:GTBP) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Institutional and Insider Ownership

8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 3.4% of GT Biopharma shares are held by insiders. Comparatively, 23.3% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for GT Biopharma and Puma Biotechnology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1	0	0	0	1.00
Puma Biotechnology	0	1	0	0	2.00

Profitability

This table compares GT Biopharma and Puma Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-116.67%
Puma Biotechnology	13.62%	27.80%	15.35%

Risk and Volatility

GT Biopharma has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Earnings and Valuation

This table compares GT Biopharma and Puma Biotechnology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35 million	($6.55)	-0.07
Puma Biotechnology	$228.40 million	1.39	$31.11 million	$0.61	10.26

Puma Biotechnology has higher revenue and earnings than GT Biopharma. GT Biopharma is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Summary

Puma Biotechnology beats GT Biopharma on 10 of the 11 factors compared between the two stocks.

About GT Biopharma

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

About Puma Biotechnology

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.